Piedmont Investment Advisors LLC raised its position in PAREXEL International Corporation (NASDAQ:PRXL) by 120.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,112 shares of the medical research company’s stock after buying an additional 8,251 shares during the period. Piedmont Investment Advisors LLC’s holdings in PAREXEL International Corporation were worth $954,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of PRXL. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of PAREXEL International Corporation by 0.8% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 7,886 shares of the medical research company’s stock worth $518,000 after buying an additional 63 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in shares of PAREXEL International Corporation by 4.5% in the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after buying an additional 73 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of PAREXEL International Corporation by 1.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,552 shares of the medical research company’s stock worth $431,000 after buying an additional 84 shares in the last quarter. Meadow Creek Investment Management LLC raised its position in shares of PAREXEL International Corporation by 7.1% in the first quarter. Meadow Creek Investment Management LLC now owns 1,980 shares of the medical research company’s stock worth $125,000 after buying an additional 132 shares in the last quarter. Finally, Baird Financial Group Inc. raised its position in shares of PAREXEL International Corporation by 2.3% in the first quarter. Baird Financial Group Inc. now owns 5,812 shares of the medical research company’s stock worth $367,000 after buying an additional 133 shares in the last quarter. 97.69% of the stock is currently owned by institutional investors and hedge funds.

PAREXEL International Corporation (PRXL) traded up 0.03% during mid-day trading on Tuesday, hitting $87.08. The stock had a trading volume of 892,208 shares. The company has a market cap of $4.42 billion, a price-to-earnings ratio of 38.28 and a beta of 0.80. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $87.45. The firm’s 50-day moving average is $78.71 and its 200 day moving average is $68.58.

PAREXEL International Corporation (NASDAQ:PRXL) last announced its quarterly earnings results on Wednesday, May 3rd. The medical research company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $529.30 million during the quarter, compared to analysts’ expectations of $529.38 million. PAREXEL International Corporation had a return on equity of 28.68% and a net margin of 5.12%. The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.89 earnings per share. Equities analysts anticipate that PAREXEL International Corporation will post $3.24 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/parexel-international-corporation-prxl-shares-bought-by-piedmont-investment-advisors-llc/1397241.html.

A number of brokerages have commented on PRXL. Jefferies Group LLC reaffirmed a “hold” rating and issued a $88.10 price objective on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Raymond James Financial, Inc. raised PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price objective on the stock. in a report on Tuesday, June 20th. Mizuho upped their price objective on PAREXEL International Corporation from $66.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, May 30th. Finally, Credit Suisse Group reaffirmed a “neutral” rating and issued a $83.00 price objective (up from $65.00) on shares of PAREXEL International Corporation in a report on Tuesday, June 6th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $74.59.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.